Switch to:
Also traded in: UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.65
HCM's Cash to Debt is ranked lower than
70% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.60 vs. HCM: 0.65 )
Ranked among companies with meaningful Cash to Debt only.
HCM' s Cash to Debt Range Over the Past 10 Years
Min: 0.65  Med: 1.79 Max: 9.93
Current: 0.65
0.65
9.93
Equity to Asset 0.36
HCM's Equity to Asset is ranked lower than
83% of the 708 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. HCM: 0.36 )
Ranked among companies with meaningful Equity to Asset only.
HCM' s Equity to Asset Range Over the Past 10 Years
Min: -0.54  Med: 0.44 Max: 0.77
Current: 0.36
-0.54
0.77
Z-Score: 7.05
WACC vs ROIC
16.63%
-16.08%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -5.50
HCM's Operating margin (%) is ranked lower than
78% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.72 vs. HCM: -5.50 )
Ranked among companies with meaningful Operating margin (%) only.
HCM' s Operating margin (%) Range Over the Past 10 Years
Min: -16.36  Med: -2.90 Max: 25.14
Current: -5.5
-16.36
25.14
Net-margin (%) 4.51
HCM's Net-margin (%) is ranked lower than
55% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.02 vs. HCM: 4.51 )
Ranked among companies with meaningful Net-margin (%) only.
HCM' s Net-margin (%) Range Over the Past 10 Years
Min: -26.4  Med: -2.34 Max: 12.87
Current: 4.51
-26.4
12.87
ROE (%) -59.21
HCM's ROE (%) is ranked lower than
89% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.02 vs. HCM: -59.21 )
Ranked among companies with meaningful ROE (%) only.
HCM' s ROE (%) Range Over the Past 10 Years
Min: -57.96  Med: -11.50 Max: 8.66
Current: -59.21
-57.96
8.66
ROA (%) 4.53
HCM's ROA (%) is ranked higher than
54% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.65 vs. HCM: 4.53 )
Ranked among companies with meaningful ROA (%) only.
HCM' s ROA (%) Range Over the Past 10 Years
Min: -16.75  Med: -2.23 Max: 3.71
Current: 4.53
-16.75
3.71
ROC (Joel Greenblatt) (%) -122.02
HCM's ROC (Joel Greenblatt) (%) is ranked lower than
82% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.79 vs. HCM: -122.02 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HCM' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -99.41  Med: -8.47 Max: 193.75
Current: -122.02
-99.41
193.75
Revenue Growth (3Y)(%) -1.80
HCM's Revenue Growth (3Y)(%) is ranked lower than
72% of the 605 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. HCM: -1.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HCM' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -31.8  Med: 20.45 Max: 38.4
Current: -1.8
-31.8
38.4
» HCM's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with HCM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:AMEX:TXMD, OTCPK:BOIRF, OTCPK:HAWPY, NAS:GWPH, OTCPK:VEGPF, OTCPK:NHKFF, OTCPK:SLUXY, OTCPK:MAYNF, NAS:ZSPH, OTCPK:SKYEY, NAS:RTRX, OTCPK:ABSCF, OTCPK:ULIHF, OTCPK:BGAIF, NAS:AERI, NAS:RMTI, NAS:BITI, NAS:ZGNX, OTCPK:EUYNF, NAS:NBRV » details
Traded in other countries:HCM.UK, HNCMF.USA,
Hutchison China Meditech Ltd and its subsidiaries is engaged in researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. It also market and sell organic and natural consumer products in Asia.

Hutchison China Meditech Ltd is a biopharmaceutical company incorporated in the Cayman Islands on December 18, 2000. The Company along with its subsidiaries is engaged in researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. The Company's clinical-stage drug candidates includes Savolitinib a potential inhibitor of the mesenchymal epithelial transition factor, or c-Met, receptor tyrosine kinase, an enzyme which has been shown to function abnormally in many types of solid tumors; Fruquintinib a selective and potent oral inhibitor of the vascular endothelial growth factor receptor, or VEGFR; Sulfatinib an oral drug candidate that selectively inhibits the tyrosine kinase activity associated with VEGFR and fibroblast growth factor receptor 1, or FGFR1, a receptor for a protein which also plays a role in tumor growth; HMPL-523 a potential oral inhibitor targeting the spleen tyrosine kinase, or Syk, a key protein involved in B-cell signaling; Epidermal growth factor receptor, or EGFR, inhibitors have revolutionized the treatment of non-small cell lung cancer with EGFR activating mutations; and theliatinib is a potent and selective oral EGFR inhibitor engineered to have greater binding affinity to wild-type EGFR proteins. The Company faces competition from different sources, including pharmaceutical, specialty pharmaceutical and biotechnology companies.

Ratios

vs
industry
vs
history
P/B 19.04
HCM's P/B is ranked lower than
97% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.82 vs. HCM: 19.04 )
Ranked among companies with meaningful P/B only.
HCM' s P/B Range Over the Past 10 Years
Min: 14.39  Med: 24.28 Max: 41.93
Current: 19.04
14.39
41.93
P/S 10.50
HCM's P/S is ranked lower than
83% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.59 vs. HCM: 10.50 )
Ranked among companies with meaningful P/S only.
HCM' s P/S Range Over the Past 10 Years
Min: 9.41  Med: 16.98 Max: 46.6
Current: 10.5
9.41
46.6
Current Ratio 1.11
HCM's Current Ratio is ranked lower than
86% of the 672 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. HCM: 1.11 )
Ranked among companies with meaningful Current Ratio only.
HCM' s Current Ratio Range Over the Past 10 Years
Min: 0.33  Med: 1.59 Max: 4.28
Current: 1.11
0.33
4.28
Quick Ratio 0.99
HCM's Quick Ratio is ranked lower than
76% of the 672 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.78 vs. HCM: 0.99 )
Ranked among companies with meaningful Quick Ratio only.
HCM' s Quick Ratio Range Over the Past 10 Years
Min: 0.23  Med: 1.21 Max: 3.87
Current: 0.99
0.23
3.87
Days Inventory 20.66
HCM's Days Inventory is ranked higher than
94% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.06 vs. HCM: 20.66 )
Ranked among companies with meaningful Days Inventory only.
HCM' s Days Inventory Range Over the Past 10 Years
Min: 14.6  Med: 127.10 Max: 164.85
Current: 20.66
14.6
164.85
Days Sales Outstanding 71.50
HCM's Days Sales Outstanding is ranked higher than
53% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.75 vs. HCM: 71.50 )
Ranked among companies with meaningful Days Sales Outstanding only.
HCM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 17.76  Med: 48.29 Max: 120.01
Current: 71.5
17.76
120.01
Days Payable 82.34
HCM's Days Payable is ranked higher than
58% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.79 vs. HCM: 82.34 )
Ranked among companies with meaningful Days Payable only.
HCM' s Days Payable Range Over the Past 10 Years
Min: 11.69  Med: 68.42 Max: 80.97
Current: 82.34
11.69
80.97

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 19.97
HCM's Price/Tangible Book is ranked lower than
95% of the 688 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. HCM: 19.97 )
Ranked among companies with meaningful Price/Tangible Book only.
HCM' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.45  Med: 5.48 Max: 33.29
Current: 19.97
0.45
33.29
Price/Median PS Value 0.62
HCM's Price/Median PS Value is ranked higher than
87% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. HCM: 0.62 )
Ranked among companies with meaningful Price/Median PS Value only.
HCM' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.12  Med: 0.92 Max: 1.22
Current: 0.62
0.12
1.22
Earnings Yield (Greenblatt) (%) -0.20
HCM's Earnings Yield (Greenblatt) (%) is ranked lower than
71% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. HCM: -0.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HCM' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -0.22  Med: 4.10 Max: 11.1
Current: -0.2
-0.22
11.1

More Statistics

Revenue (TTM) (Mil) $178.2
EPS (TTM) $ -0.31
Short Percentage of Float0.01%
52-Week Range $9.80 - 14.70
Shares Outstanding (Mil)120.57

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 122 153 189
EPS ($) -0.17 -0.06 0.08
EPS w/o NRI ($) -0.17 -0.06 0.08
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for HCM

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer Jun 20 2016
Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer Jun 20 2016
Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer Jun 20 2016
Hutchison China Meditech Limited: Savolitinib Global Phase II Trial Initiated Jun 20 2016
Block Admission Jun 15 2016
Hutchison China MediTech webcast presentation now available for on-demand viewing: dbVIC - Deutsche... Jun 13 2016
International companies to host live webcasts at Deutsche Bank's June 9th and 10th Depositary... Jun 06 2016
Hutchison China MediTech to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on... Jun 06 2016
Total Voting Rights May 31 2016
AACR 2016: Activity of Savolitinib against MET Ex14 mutations and resistance to METi through... May 15 2016
Chi-Med Completes Enrollment of 416 Patients in Pivotal Phase III FRESCO Trial with Fruquintinib in... May 13 2016
Chi-Med Completes Enrollment of 416 Patients in Pivotal Phase III FRESCO Trial with Fruquintinib in... May 13 2016
Chi-Med Completes Enrollment of 416 Patients in Pivotal Phase III FRESCO Trial with Fruquintinib in... May 13 2016
Chi-Med Completes Enrollment of 416 Patients in Pivotal Phase III FRESCO Trial with Fruquintinib in... May 13 2016
Chi-Med to Participate in Two Healthcare Investor Conferences in May May 03 2016
Chi-Med to Participate in Two Healthcare Investor Conferences in May May 03 2016
Chi-Med to Participate in Two Healthcare Investor Conferences in May May 03 2016
Total Voting Rights Apr 29 2016
Results of Annual General Meeting Apr 27 2016
Pharma fight! Should you buy GlaxoSmithKline plc, Smith & Nephew plc or Hutchison China MediTech... Apr 26 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)